Bruce L Levine

List of Publications by Citations

127 papers	27,169 citations	53 h-index	135 g-index
135 ext. papers	33,247 ext. citations	12 avg, IF	6.79 L-index

#	Paper	IF	Citations
127	Chimeric antigen receptor T cells for sustained remissions in leukemia. *New England Journal of Medicine*, **2014**, 371, 1507-17	59.2	3305
126	Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. *New England Journal of Medicine*, **2011**, 365, 725-33	59.2	2502
125	Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. *New England Journal of Medicine*, **2013**, 368, 1509-1518	59.2	2406
124	Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. *New England Journal of Medicine*, **2018**, 378, 439-448	59.2	2275
123	T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. *Science Translational Medicine*, **2011**, 3, 95ra73	17.5	1656
122	Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. *Science Translational Medicine*, **2015**, 7, 303ra139	17.5	1071
121	Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. *New England Journal of Medicine*, **2014**, 370, 901-10	59.2	1018
120	Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. *New England Journal of Medicine*, **2017**, 377, 2545-2554	59.2	951
119	A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. *Science Translational Medicine*, **2017**, 9,	17.5	697
118	Engineered T cells: the promise and challenges of cancer immunotherapy. *Nature Reviews Cancer*, **2016**, 16, 566-81	31.3	662
117	Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. *Nature Medicine*, **2018**, 24, 563-571	50.5	649
116	Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. *Cancer Discovery*, **2016**, 6, 664-79	24.4	603
115	Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. *Cancer Immunology Research*, **2014**, 2, 112-20	12.5	558
114	NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. *Nature Medicine*, **2015**, 21, 914-921	50.5	543
113	Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. *Science Translational Medicine*, **2012**, 4, 132ra53	17.5	456
112	CRISPR-engineered T cells in patients with refractory cancer. *Science*, **2020**, 367,	33.3	448
111	Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. *New England Journal of Medicine*, **2015**, 373, 1040-7	59.2	417

110	Gene transfer in humans using a conditionally replicating lentiviral vector. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 17372-7	11.5	395
109	Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. *Nature*, **2018**, 558, 307-312	42.4	362
108	B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. *Journal of Clinical Investigation*, **2019**, 129, 2210-2221	15.9	312
107	Global Manufacturing of CAR T Cell Therapy. *Molecular Therapy - Methods and Clinical Development*, **2017**, 4, 92-101	6.4	310
106	Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. *Nature Medicine*, **2018**, 24, 1499-1503	50.5	286
105	PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. *Blood*, **2017**, 129, 1039-1041	2.2	285
104	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. *Blood*, **2016**, 127, 1117-27	2.2	282
103	Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. *Nature Medicine*, **2005**, 11, 1230-7	50.5	256
102	Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. *Blood*, **2016**, 127, 1044-51	2.2	251
101	Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. *Gastroenterology*, **2018**, 155, 29-32	13.3	209
100	Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. *Science Translational Medicine*, **2018**, 10,	17.5	205
99	A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. *Blood*, **2006**, 107, 1325-31	2.2	190
98	Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. *Science*, **1997**, 276, 273-6	33.3	182
97	Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer. *Cancer Immunology Research*, **2017**, 5, 1152-1161	12.5	181
96	Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. *Blood*, **2017**, 130, 2317-2325	2.2	180
95	Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. *Blood*, **2003**, 102, 2004-13	2.2	169
94	Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. *Nature Medicine*, **2002**, 8, 47-53	50.5	152
93	A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. *Clinical Cancer Research*, **2013**, 19, 4801-15	12.9	141

92	Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. *Blood*, **2011**, 117, 788-97	2.2	129
91	Reducing Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells. *Cancer Immunology Research*, **2018**, 6, 1100-1109	12.5	105
90	Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. *Clinical Cancer Research*, **2014**, 20, 1355-65	12.9	104
89	Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. *Molecular Therapy*, **2019**, 27, 1919-1929	11.7	101
88	Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. *Human Gene Therapy*, **2013**, 24, 245-58	4.8	99
87	Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. *Stem Cells and Development*, **1998**, 7, 437-48		99
86	Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia. *Clinical Cancer Research*, **2018**, 24, 6175-6184	12.9	98
85	T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. *Cancer Immunology Research*, **2013**, 1, 26-31	12.5	94
84	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. *JCI Insight*, **2018**, 3,	9.9	90
83	Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. *Cytotherapy*, **2017**, 19, 867-880	4.8	85
82	Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells. *Clinical Cancer Research*, **2009**, 15, 4499-507	12.9	81
81	Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology*, **2020**, 38, 415-422	2.2	80
80	Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV. *Blood*, **2013**, 121, 1524-33	2.2	76
79	Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. *Molecular Therapy*, **2018**, 26, 269-279	11.7	63
78	T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. *Blood Advances*, **2019**, 3, 2812-2815	7.8	61
77	Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. *Oncologist*, **2016**, 21, 608-17	5.7	60
76	International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19. *Cytotherapy*, **2020**, 22, 482-485	4.8	59
75	B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study. *Blood*, **2016**, 128, 1147-1147	2.2	53

74	Efficacy and Safety of CTL019 in the First US Phase II Multicenter Trial in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia: Results of an Interim Analysis. *Blood*, **2016**, 128, 2801-2801	2.2	46
73	CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. *Journal of Clinical Investigation*, **2020**, 130, 673-685	15.9	45
72	Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. *Journal of Clinical Oncology*, **2020**, 38, 2862-2871	2.2	45
71	CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success. *Frontiers in Immunology*, **2018**, 9, 2740	8.4	45
70	Adoptive immunotherapy: good habits instilled at youth have long-term benefits. *Immunologic Research*, **2008**, 42, 182-96	4.3	43
69	Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells. *CPT: Pharmacometrics and Systems Pharmacology*, **2019**, 8, 285-295	4.5	42
68	The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy. *Clinical Cancer Research*, **2015**, 21, 2840-50	12.9	42
67	Chimeric antigen receptor-T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods. *Cytotherapy*, **2019**, 21, 224-233	4.8	40
66	The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. *Cytotherapy*, **2020**, 22, 57-69	4.8	39
65	Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma. *Blood*, **2018**, 132, 1022-1026	2.2	38
64	Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. *Blood*, **2011**, 117, 63-71	2.2	35
63	CAR T-cell product performance in haematological malignancies before and after marketing authorisation. *Lancet Oncology, The*, **2020**, 21, e104-e116	21.7	35
62	Refractory Cytokine Release Syndrome in Recipients of Chimeric Antigen Receptor (CAR) T Cells. *Blood*, **2014**, 124, 2296-2296	2.2	34
61	Efficient Trafficking of Chimeric Antigen Receptor (CAR)-Modified T Cells to CSF and Induction of Durable CNS Remissions in Children with CNS/Combined Relapsed/Refractory ALL. *Blood*, **2015**, 126, 3769-3769	2.2	34
60	Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. *Cytotherapy*, **2017**, 19, 250-262	4.8	32
59	Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL. *Blood*, **2014**, 124, 1982-1982	2.2	32
58	Decade-long leukaemia remissions with persistence of CD4 CAR T cells.. *Nature*, **2022**,	50.4	30
57	T lymphocyte engineering ex vivo for cancer and infectious disease. *Expert Opinion on Biological Therapy*, **2008**, 8, 475-89	5.4	28

56	Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. *Blood*, **2016**, 128, 974-974	2.2	27
55	Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide. *Blood*, **2016**, 128, 5702-5702	2.2	23
54	Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. *Journal of Clinical Oncology*, **2021**, 39, 3044-3055	2.2	23
53	Emerging trends in COVID-19 treatment: learning from inflammatory conditions associated with cellular therapies. *Cytotherapy*, **2020**, 22, 474-481	4.8	21
52	T cell engineering as therapy for cancer and HIV: our synthetic future. *Philosophical Transactions of the Royal Society B: Biological Sciences*, **2015**, 370, 20140374	5.8	20
51	T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL. *Blood*, **2013**, 122, 67-67	2.2	16
50	Efficacy and Safety of Humanized Chimeric Antigen Receptor (CAR)-Modified T Cells Targeting CD19 in Children with Relapsed/Refractory ALL. *Blood*, **2015**, 126, 683-683	2.2	15
49	CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. *Journal of Clinical Investigation*, **2021**, 131,	15.9	15
48	Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 57-57	2.2	14
47	Phase I study of multi-gene cell therapy in patients with peripheral artery disease. *Vascular Medicine*, **2016**, 21, 21-32	3.3	14
46	Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL. *Blood*, **2013**, 122, 4162-4162	2.2	13
45	Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer. *Molecular Therapy*, **2020**, 28, 2367-2378	11.7	13
44	Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL. *Blood*, **2013**, 122, 873-873	2.2	12
43	T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL. *Blood*, **2014**, 124, 380-380	2.2	12
42	Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CAR. *Blood*, **2016**, 128, 281-281	2.2	11
41	Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children. *Blood Advances*, **2020**, 4, 5174-5183	7.8	10
40	CAR T cell viability release testing and clinical outcomes: is there a lower limit?. *Blood*, **2019**, 134, 1873-1875	2.2	9
39	Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy. *Current Hematologic Malignancy Reports*, **2017**, 12, 335-343	4.4	9

38	IMCT-15PILOT STUDY OF T CELLS REDIRECTED TO EGFRvIII WITH A CHIMERIC ANTIGEN RECEPTOR IN PATIENTS WITH EGFRvIII+ GLIOBLASTOMA. *Neuro-Oncology*, **2015**, 17, v110.4-v111	1	9
37	A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies. *Cytotherapy*, **2019**, 21, 1081-1093	4.8	7
36	Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL. *Blood*, **2014**, 124, 1983-1983	2.2	6
35	Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. *American Journal of Hematology*, **2016**, 91, 453-60	7.1	6
34	BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. *Journal of Clinical Investigation*, **2021**, 131,	15.9	6
33	Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma. *Annals of Translational Medicine*, **2016**, 4, 13	3.2	5
32	The Opioid Epidemic and Psychiatry: The Time for Action Is Now. *Psychiatric Services*, **2019**, 70, 1168-1171	3.3	4
31	Powered and controlled T-cell production. *Nature Biomedical Engineering*, **2018**, 2, 148-150	19	4
30	Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL. *Blood*, **2012**, 120, 717-717	2.2	4
29	Cellular Kinetics of Chimeric Antigen Receptor T Cells (CTL019) in Patients with Relapsed/Refractory CD19+ Leukemia. *Blood*, **2016**, 128, 220-220	2.2	4
28	CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc).. *Blood*, **2012**, 120, 2604-2604	2.2	4
27	The Coronavirus Pandemic: A Pitfall or a Fast Track for Validating Cell Therapy Products?. *Stem Cells and Development*, **2021**, 30, 119-127	4.4	4
26	Approaches of T Cell Activation and Differentiation for CAR-T Cell Therapies. *Methods in Molecular Biology*, **2020**, 2086, 203-211	1.4	4
25	Accelerating the development of innovative cellular therapy products for the treatment of cancer. *Cytotherapy*, **2020**, 22, 239-246	4.8	3
24	Production of Human CRISPR-Engineered CAR-T Cells. *Journal of Visualized Experiments*, **2021**,	1.6	3
23	Novel gene and cellular therapy approaches for treating HIV. *Discovery Medicine*, **2016**, 21, 283-92	2.5	3
22	Adaptation in Delivering Integrated Care: The Tension Between Care and Evidence-Based Practice. *Psychiatric Services*, **2018**, 69, 1029-1031	3.3	2
21	Advances in automated cell washing and concentration. *Cytotherapy*, **2021**, 23, 774-786	4.8	2

20	Good Manufacturing Practices Facilities for Cellular Therapy **2018**, 177-185		1
19	Prolonged T Cell Persistence, Homing to Marrow and Selective Targeting of Antigen Positive Tumor in Multiple Myeloma Patients Following Adoptive Transfer of T Cells Genetically Engineered to Express an Affinity-Enhanced T Cell Receptor Against the Cancer Testis Antigens NY-ESO-1 and Lage-1. *Blood*, **2012**, 120, 755-755	2.2	1
18	Engineering T Cells to Survive and Thrive in the Hostile Tumor Microenvironment. *Current Opinion in Biomedical Engineering*, **2021**, 100360	4.4	1
17	Adoptive T-cell therapy for Hodgkin lymphoma. *Blood Advances*, **2021**, 5, 4291-4302	7.8	1
16	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. *Clinical Cancer Research*, **2021**, 27, 6580-6590	12.9	1
15	Advances in engineering and synthetic biology toward improved therapeutic immune cells. *Current Opinion in Biomedical Engineering*, **2021**, 20, 100342	4.4	1
14	Predicting T-cell quality during manufacturing through an artificial intelligence-based integrative multiomics analytical platform. *Bioengineering and Translational Medicine*,e10282	14.8	0
13	B-cell maturation antigen chimeric antigen receptor T-cell re-expansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitor-based combination therapy. *British Journal of Haematology*, **2021**, 193, 851-855	4.5	0
12	Autologous CD4⁺ T Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. *Molecular Therapy*, **2021**, 29, 626-635	11.7	0
11	Exploring synthetic immunity: From boutique to global. *Human Vaccines and Immunotherapeutics*, **2017**, 13, 2204-2206	4.4	
10	Assays for the Release of Cellular Gene Therapy Products307-318		
9	Stable Gene Transfer and Expression in Human Primary T-Cells by the Sleeping Beauty Transposon System.. *Blood*, **2005**, 106, 5539-5539	2.2	
8	CD28-Mediated Regulation of Multiple Myeloma Cell Proliferation and Survival.. *Blood*, **2005**, 106, 355-355	2.2	
7	Costimulated, Tumor-Derived Donor Lymphocyte (TDL) Infusion for B-Cell Tumor Relapse After Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*, **2010**, 116, 683-683	2.2	
6	Adoptive Immunotherapy with Autologous CD3/CD28-Costimulated T-Cells After Fludarabine-Based Chemotherapy in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2011**, 118, 2855-2855	2.2	
5	Combination Immunotherapy After ASCT for Multiple Myeloma (MM) Using MAGE-A3/Poly-ICLC Immunizations Followed by Vaccine-Primed and Activated Autologous T-Cells. *Blood*, **2012**, 120, 352-352	2.2	
4	Sustained Functional T Cell Persistence and B Cell Aplasia Following CD19-Targeting Adoptive T Cell Immunotherapy for Relapsed, Refractory CD19+ Malignacy. *Blood*, **2012**, 120, 756-756	2.2	
3	Pre-Emptive T-Rapa Cell DLI for Therapy of High-Risk Lymphoma After Low-Intensity Allogeneic HCT. *Blood*, **2012**, 120, 471-471	2.2	

List of Publications

2	Adoptive Transfer of Autologous CD25-Depleted, CD3/CD28-Costimulated T Cells After Cyclophosphamide - Fludarabine Chemotherapy in Patients with Low-Grade Follicular Lymphoma: Long-Term Follow up. *Blood*, **2012**, 120, 1631-1631	2.2
1	The peril of the promise of speculative cell banking: Statement from the ISCT Committee on the Ethics of Cell and Gene Therapy.. *Cytotherapy*, **2022**,	4.8